Skip to main content
 

Letters We've Submitted

CSC Comments on Docket No. FDA-2017-N-2732 for July 13, 2017 Oncologic Drugs Advisory Committee Meeting on Biologics License Applications 761028 and 761074 (July 2017)

CSC Comments on the Proposed Office of Patient Affairs (June 2017)

CSC Comment Letter on ISPOR Value Assessment Frameworks (May 2017)

CSC Response to President Trump's FY18 Budget Proposal (May 2017)

CSC Letter to Senate Leadership on AHCA (May 2017)

CSC Comment Letter on Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products (April 2017)

CSC Comment Letter to ICER on the Patient Engagement Guide (April 2017)

CSC Position Letter on Step Therapy (March 2017)

CSC's Comment Letter to ICER on the Value Assessment Framework Update (March 2017)

CSC’s Comment Letter to ICER on the Background and Scope Document on Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer (Long Version - March 2017)

CSC’s Comment Letter to ICER on the Background and Scope Document on Poly ADP-ribose polymerase (PARP) Inhibitors for Ovarian Cancer (Short Version - March 2017)

Friends of CPI Letter to Dr. Woodcock (March 2017)

CSC Comment Letter to ICER on Lung Cancer Evidence Report Framework (September 2016)

CSC Comment Letter to ICER on Value Assessment Framework (September 2016)

CSC Comment Letter on PDUFA VI Goals Letter (August 2016)

CSC Comment Letter on MACRA Proposed Rule (June 2016)

CSC Comment Letter on Medicare Part B Proposed Rule (May 2016)

CSC Comment Letter to ICER on Assessment of Treatment Options for Multiple Myeloma (April 2016)

CSC Comments on Payment and Benefit Parameters (December 2015)

CSC Letter to Woodcock (December 2015)

Friends of CPI Letter to Burwell (December 2015)

NCCN Letter to Dr. Carlson—NCCN Evidence Blocks Letter (December 2015)

CSC Comments Regarding MACRA (November 2015)

Alliance Letter to Burwell (September 2015)

CSC Comments on Revisions to the Physician Fee Schedule (September 2015)

CSC Comments on Prescription Drug Fee User Act (PDUFA) (August 2015)

CSC Letter to National Government Services Medical Policy Unit (August 2015)

CSC's Response to ASCO Value Framework (August 2015)

Letter to Iowa Drug Utilization Review Commission Regarding Prior Authorization Restrictions (July 2015)

Comments on 21st Century Cures Act (July 2015)

Comments on Ways to Improve Outcomes for Medicare Patients with Chronic Conditions (June 2015)

USPSTF Early Screening for Depression

Comments on the Innovation for Healthier Americans Report (February 2015)

Comments Regarding Cancer Care Payment Reform Act of 2015 (January 2015)

Comments on Proposal Regarding Transparency for Incentive Payments (January 2015)

CSC Comments on FDA Activities for Patient Participation in Medical Product Discussions (December 2014)

CSC CEO Kim Thiboldeaux on the importance of patient perceptions of value in cancer care (Huffington Post- July 2014)

CSC Concerns with Proposed Rule Changes to Medicare Part D’s 6 Protected Classes (March 2014)

CSC Supports FDA Safety Over Sequestration Act (September 2013)—Senate

CSC Supports FDA Safety Over Sequestration Act (September 2013)

CSC Drug Shortage Comments (April 2012)